La Jolla, CA, United States of America

John C Timmer

USPTO Granted Patents = 41 

 

 

Average Co-Inventor Count = 5.6

ph-index = 6

Forward Citations = 142(Granted Patents)


Location History:

  • La Jolla, CA (US) (2015 - 2024)
  • San Diego, CA (US) (2015 - 2024)

Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
41 patents (USPTO):Explore Patents

Title: John C. Timmer: Innovator in Therapeutic Protein Design

Introduction

John C. Timmer, based in La Jolla, California, is a prolific inventor with an impressive portfolio of 36 patents to his name. His work primarily focuses on therapeutic proteins that engage specific receptors of the immune system, addressing various medical needs through innovative design and application.

Latest Patents

Among his latest contributions to the field, Timmer has developed multivalent and multispecific OX40-binding fusion proteins. This invention targets the OX40 receptor, a critical component of the immune response, providing new avenues for treatment in immunotherapy. Additionally, his invention of multispecific polypeptide constructs is noteworthy, as these constructs bind to CD3, along with a second antigen, enhancing T cell activity. These polypeptides can either engage costimulatory receptors to boost immune responses or bind inhibitory receptors to counteract immune suppression. The combination of these innovative designs offers significant therapeutic, diagnostic, and prophylactic potential.

Career Highlights

Timmer's career has been marked by his pivotal roles at companies like Inhibrx, Inc. and Inhibrx Biosciences, Inc., where he has contributed his expertise in protein engineering and therapeutic development. His work not only emphasizes the importance of innovative technologies in medicine but also showcases the impact of well-designed molecules on patient outcomes.

Collaborations

Throughout his career, Timmer has collaborated with esteemed colleagues, including Brendan P. Eckelman and Quinn L. Deveraux. These partnerships have fostered a collaborative spirit necessary for advancing research and development in the field of immunotherapy.

Conclusion

John C. Timmer stands as a leading figure in the realm of innovative therapeutic protein design. His significant patent portfolio and collaborations underscore his commitment to enhancing immunotherapeutic strategies through cutting-edge research and development. As the field progresses, Timmer's contributions are sure to continue influencing advancements in medical treatment and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…